Drug safety: Further actions needed to improve fda’s postmarket decision-making process

May 9, 2007
GAO_drug_safety_507
172.8 KB

GAO report found that FDA lacked clear and effective processes for making decisions about, and providing management oversight of, postmarket drug safety issues.

IssuesHealth
You Might Also Be Interested In
June 15, 2020
CR comments to FTC on Funeral Industry Practices Rule
press release
May 14, 2020
Consumer Reports supports bill to strengthen privacy protections for data collected to combat coronavirus
May 7, 2020
Consumer letter opposing COVID liability shield for businesses
April 30, 2020
Coalition letter opposing COVID liability shield for businesses